Joint Bridging Topic workshop: "Artificial intelligence in antibodies & vaccines development"

The advent of artificial intelligence (AI) has opened new opportunities for vaccine and antibody development. AI-driven approaches have for example the potential to rapidly advance the identification of immunogens and novel adjuvant candidates with optimal safety and efficacy profiles. 

To provide more insights into the transformative impact of AI on translation and product development driven activities, the Bridging Topics “Vaccines” and “Antibody-based Therapies” organize a joint Bridging Topic workshop. Participation in this workshop is open to all interested members of the DZIF as well as the extended scientific community. 

With this workshop, we aim to improve our knowledge in AI-supported development of safe and effective vaccines and antibodies, as well as foster interdisciplinary collaborations. This will be the first workshop related to AI and R&D within the DZIF Vaccine and Antibody Bridging Topics, emphasizing the ambition to further drive innovative AI technologies within the DZIF.

Language
English

Program
View the program

Registration
Deadline: October 15, 2025 (the maximum number of participants has already been reached; no further registrations are possible) 

Scientific organization
Prof. Dr. Florian Klein, Coordinator of the Bridging Topic “Antibody-Based Therapies”
Klaus Schwamborn, Ph.D., Coordinator of the Bridging Topic “Vaccines”

Contact
Agnieszka Mitulski
Send an email

Susanne Salomon
Send an email